ClinicalTrials.gg
RecruitingNCT07064226MI-RICORDOUpdated Feb 13, 2026

Validation of a Digital Intervention to Rehabilitate Cognitive Resources

An interventional study of RICORDO and Treatment as Usual (TAU) in Mild Cognitive Impairment (MCI), Subjective Memory Complaint and Dementia Alzheimer Type, sponsored by Fondazione Don Carlo Gnocchi ETS. Recruiting at 1 site in Italy. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Fondazione Don Carlo Gnocchi ETS · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 175 studies in Cognitive Dysfunction with a site in Italy — 74 open to participants now, 87 under way, 6 of them phase 3. Cognitive Dysfunction · Italy.

Planned enrollment
44th of 111
102 · median 80
Started
2025
with 23 others
No phase
93 of 175
42 open now
Primary completion
2027-08
later than 59 of 86 live
Registered
137th of 175
by date
Lead sponsor
7 of 175
Fondazione Don Carlo Gnocchi ETS

Among the 175 studies in Cognitive Dysfunction with a site in Italy, this one is the 44th largest by planned enrollment of the 111 interventional ones that give a count, is one of 24 that started in 2025, is one of 93 with no phase, reaches primary completion later than 59 of the 86 other live ones, and was the 137th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

74 of the 175 studies in Cognitive Dysfunction with a site in Italy are open now. Recruiting first, the newest first:

68 more — sign in →

All 74 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 175 studies in Cognitive Dysfunction with a site in Italy, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the use of a digital cognitive rehabilitation system named RICORDO, that is flexible and capable of adapting the rehabilitation pathway according to the needs and capacity of the patients will prove effective for subjects with Subjective Memory Complaint or with Mild Cognitive Impairment or with Mild Dementia.

The main questions it aims to answer are:

Will the RICORDO rehabilitation treatment, lead to an improvement in the global cognitive level? Will the RICORDO rehabilitation treatment lead to improved activation of participants in managing their own health and healthcare? Researchers will compare the multidomain cognitive rehabilitation strategy of RICORDO digital solution, with a standard paper pencil rehabilitation care (usual care).

Participants will undergo a comprehensive neuropsychological evaluation immediately before, immediately after and six months after the completion of the rehabilitation program.

Both interventions, the experimental and the usual care, will last 5 weeks, with 3 weekly sessions of 45 minutes each and can be done autonomously by the patient at home.

03

Conditions studied

  • Mild Cognitive Impairment (MCI)
  • Subjective Memory Complaint
  • Dementia Alzheimer Type

Keywords

  • telerehabilitation
  • Alzheimer disease
  • cognitive decline
  • cognitive rehabilitation
  • Digital medicine
  • Dementia
  • Mild Cognitive Impairment
  • neuroimaging
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (MoCA) score > 17.79;
  2. Clinical Dementia Rating (CDR) Scale score ≤ 1;
  3. Education level > 3 years;
  4. Age ≥ 65 years;
  5. to participate, confirmed by signing the consent form;
  6. Availability of a caregiver/study partner able to support the participant;
  7. Stable pharmacological treatment (past 3 months) with acetylcholinesterase inhibitors, if applicable.

Exclusion criteria

Exclusion criteria:

  1. Presence of dysmetria or marked auditory/visual or communication disorders preventing the participation to the trial;
  2. Presence of ongoing rehabilitation program at the time of enrollment or in the 3 months prior to enrollment;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    RICORDO

    Participants will carry out telerehabilitation using a digital platform \[http://www.ricordo-dtx.com/\], at home, autonomously.

    Other: RICORDO

  • Active comparator
    Treatment as Usual (TAU)

    Participants will follow a traditional paper-and-pencil rehabilitation protocol at home, autonomously.

    Other: Treatment as Usual (TAU)

Interventions

  • OtherRICORDO

    During the RICORDO intervention, participants will engage in a multidomain cognitive telerehabilitation program using a digital platform (\[http://www.ricordo-dtx.com/\]), which allows for personalized interventions through an adaptive algorithm allowing an increment in task difficulties according to patients' needs. The treatment can be self-administered by the patient at home. The program lasts five weeks, with three treatment sessions per week, each lasting approximately 45 minutes. The active control group (TAU) will undergo the same type of treatment with the following differences: the digital platform will not be used, as the treatment will consist solely of paper-and-pencil exercises; and there will be no personalization of the exercises, since automatic adaptation is not possible.

  • OtherTreatment as Usual (TAU)

    As described above, this type of intervention will consist in a multidomain cognitive rehabilitation treatment to be self administered by the participants at home with pencil paper excercises. Treatment will last 5 weeks, 3 sessions per week, each lasting approximately 45 minutes. The treatment will follow a predefined incremental difficulty structure since no personalization is available.

06

What researchers measure

Primary outcomes

  1. Change in global cognitive functioning and subdomains measured by Montreal Cognitive Assessment MoCA

    MoCA is a screening test for cognitive deficits. It measures the global cognitive functioning and includes several tasks involving different domains: visuospatial/executive function, language, selective and sustained attention, abstraction, memory and orientation. Score ranges from 0 to 30 with higher scores indicating better general cognitive performance.

    Time frame: Baseline, after 5 weeks (End of treatment), 6 months after baseline (Follow-up)

  2. Change in Activation level of Patients measured by Patient Activation Measure 13 (PAM13)

    The Patient Activation Measure (PAM-13) is a 13-item instrument designed to evaluate an individual's knowledge, skills, and confidence in effectively managing their health and healthcare. The total PAM-13 score ranges from 0 to 100, with higher scores indicating greater levels of activation and more favorable outcomes. Individuals classified in the lowest activation level typically lack awareness of their role in managing their health, demonstrate limited health-related knowledge, and possess underdeveloped self-management abilities. In contrast, those in the highest activation level exhibit proactive health behaviors, possess well-established self-management competencies, and demonstrate resilience in response to stress or health-related changes.

    Time frame: Baseline, after 5 weeks (End of treatment), 6 months after baseline (Follow-up)

Secondary outcomes

  1. Change in memory in everyday situations measured by Everyday Memory Questionnaire Revised

    The Everyday Memory Questionnaire (EMQ) is a self-report instrument designed to assess subjective experiences of memory failure in daily life. The revised version comprises 13 items, each describing a specific memory-related situation. Respondents rate the frequency with which they experience each situation using a 5-point Likert scale. The total score is calculated as the sum of all item responses and ranges from 0 to 52, with higher scores indicating a greater frequency of everyday memory lapses.

    Time frame: Baseline, after 5 weeks (End of treatment), 6 months after baseline (Follow-up)

  2. Change in depressive symptoms measured by Beck Depression Inventory II

    The Beck Depression Inventory II is a self report questionnaire to evaluate the depression level. It consists of 21 questions, each scored on a 4-point scale, with a total score ranging from 0 to 63. The total score is calculated by summing the responses to all 21 questions. HIgher scores indicate more severe deflection of mood tone. The BDI-II can be used to assess the effectiveness of treatment interventions.

    Time frame: Baseline, after 5 weeks (End of treatment), 6 months after baseline (Follow-up)

  3. Change in mood measured by Positive and Negative Affect Scale (PANAS)

    The Positive and Negative Affect Schedule (PANAS) is a self-administered questionnaire designed to assess affective states. It consists of two distinct subscales that measure positive affect (PA) and negative affect (NA), respectively. Each subscale comprises ten descriptive adjectives, with participants rating the extent to which they have experienced each emotion on a 5-point Likert scale, ranging from 1 (very slightly or not at all) to 5 (extremely). The overall PANAS score is calculated by summing the ratings for the items within each subscale, yielding separate PA and NA scores. Score ranges from 10 to 50. Higher scores on each subscale reflect greater intensity of the corresponding affect. In scoring, values from the positive affect items contribute to the PA score, while values from the negative affect items contribute to the NA score.

    Time frame: Baseline, after 5 weeks (End of treatment), 6 months after baseline (Follow-up)

  4. Change in anxiety level measured by State-Trait Anxiety Inventory (STAI- Y state)

    The STAI-Y is a frequeltly used self-reported questionnaire to measure state anxiety (20 items). Each item is rated on a 4-point scale (from "Almost Never" to "Almost Always"). STAI is scored by summing ratings for each item (range 0-80). Higher scores indicate greater anxiety.

    Time frame: Baseline, after 5 weeks (End of treatment), 6 months after baseline (Follow-up)

  5. Change in Language and Executive Functions evaluated by Phonemic/Semantic alternate fluency test

    The Phonemic/Semantic Alternate Fluency Test (Costa et al., 2014) is a verbal fluency task designed to assess executive functioning, particularly cognitive flexibility and lexical access. Participants are required to alternately generate words beginning with a specific letter (phonemic fluency) and belonging to a specific semantic category (semantic fluency) within a limited time frame. This alternating condition increases task complexity and places greater demands on mental set shifting compared to traditional fluency tasks.

    Time frame: Baseline, after 5 weeks (End of treatment), 6 months after baseline (Follow-up)

  6. Change in visuospatial abilities evaluated by Benson Figure Copy and recall

    The Benson Figure Test is a neuropsychological assessment used to evaluate visuospatial abilities, visual memory, and constructional skills. Patients are asked to copy a complex figure and to recall it after 10 minutes.

    Time frame: Baseline, after 5 weeks (End of treatment), 6 months after baseline (Follow-up)

  7. Change in visuoperceptual and attentional abilities measured by Trail Making Test (TMT parts A and B)

    The Trail Making Test (TMT) is a neuropsychological test used to assess attention, mental flexibility, and motor coordination. It involves connecting a sequence of targets (numbers or alternating numbers and letters) as quickly as possible, while maintaining accuracy. The test has two parts, A and B, with Part B requiring a switch in task requirements. The scoring of TMT consists in the time used to complete each part of the test. Higher execution times indicate poorer performance.

    Time frame: Baseline, after 5 weeks (End of treatment), 6 months after baseline (Follow-up)

  8. Change in patient's self-rated health measured by EuroQol five dimensions (5D) and five levels (5L)

    The EQ-5D-5L is a standardized measure of health status, consisting of two parts: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system evaluates five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS captures the patient's self-rated health on a vertical visual analogue scale, with endpoints labeled 'The best health you can imagine' (scored as 100) and 'The worst health you can imagine' (scored as 0).

    Time frame: Baseline, after 5 weeks (End of treatment), 6 months after baseline (Follow-up)

  9. Change in immediate recall memory measured by the Free and Cued Selective Reminding Test (FCSRT)

    The patient is instructed to freely and cuedly recall as many items as possible. The score corresponds to the total number of recalled items across the three immediate trials (range: 0-36). Higher scores indicate greater memory performance.

    Time frame: Baseline, after 5 weeks (End of treatment), 6 months after baseline (Follow-up)

  10. Change in delayed recall memory measured by the Free and Cued Selective Reminding Test (FCSRT)

    The patient is asked to recall as many items as possibile after 30 min from learning phase. The score corresponds to the number of recalled items across the three trials (range: 0-12).

    Time frame: Baseline, after 5 weeks (End of treatment), 6 months after baseline (Follow-up)

  11. Change in Theory of Mind ability evaluated by Yoni-48 task

    The Yoni-48 task is a computerized measure of Theory of Mind (ToM), specifically designed to assess first- and second-order affective and cognitive mentalizing. It consists of 48 visual stimuli presented on a computer screen, where a cartoon character named "Yoni" is shown with four surrounding elements. The mentalizing stimuli comprise 21 affective and 21 cognitive ToM items and are divided into 16 first-order (8 affective, 8 cognitive) and 26 second-order (13 affective and 13 cognitive) ToM stimuli. the remaining 6 are non mentalizing - control items. The scores are summed and adjusted for demographics to compute an accuracy index ranging from 0 (poorer performance) to 1 (better performance).

    Time frame: Baseline, after 5 weeks (End of treatment), 6 months after baseline (Follow-up)

Other outcomes

  1. Changes in Fractional Anisotropy (FA) and Mean Diffusivity (MD) as detected by Diffusion Weighted Magnetic Resonance Imaging (DWI).

    DWI sequences will be collected to detect changes in FA and MD (these indices are complementary and need to be considered together to be interpreted) to evaluate structural connectivity.

    Time frame: Baseline, after 5 weeks (End of treatment), 6 months after baseline (Follow-up)

  2. Changes in Functional Connectivity (FC) as detected by resting state functional Magnetic Resonance Imaging (rs-fMRI)

    Resting-State fMRI (Multi echo - Multi-Band) images will be collected for the assessment of the FC before and after intervention.

    Time frame: Baseline, after 5 weeks (End of treatment), 6 months after baseline (Follow-up)

07

Study locations

1 of 1 sites recruiting
  • IRCCS Fondazione Don Carlo Gnocchi ONLUS; Center of Advance Diagnostic and Therapy ( CADiTeR)
    Milan, 20148, Italy
    Recruiting
08

References and documents

Publications

  • Spielberger CD, Gorsuch RL, Lushene RE, et al. State-Trait Anxiety Inventory for adults: manual, instrument and scoring guide. Palo Alto: Mind Garden; 1983
  • BECK AT, WARD CH, MENDELSON M, MOCK J, ERBAUGH J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561-71. doi: 10.1001/archpsyc.1961.01710120031004. No abstract available. PubMed 13688369 ↗
  • Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993 Nov;43(11):2412-4. doi: 10.1212/wnl.43.11.2412-a. No abstract available. PubMed 8232972 ↗
  • Balestroni G, Bertolotti G. [EuroQol-5D (EQ-5D): an instrument for measuring quality of life]. Monaldi Arch Chest Dis. 2012 Sep;78(3):155-9. doi: 10.4081/monaldi.2012.121. Italian. PubMed 23614330 ↗
  • Isernia S, Rossetto F, Shamay-Tsoory S, Marchetti A, Baglio F. Standardization and normative data of the 48-item Yoni short version for the assessment of theory of mind in typical and atypical conditions. Front Aging Neurosci. 2023 Jan 12;14:1048599. doi: 10.3389/fnagi.2022.1048599. eCollection 2022. PubMed 36711213 ↗
  • Possin KL, Laluz VR, Alcantar OZ, Miller BL, Kramer JH. Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementia. Neuropsychologia. 2011 Jan;49(1):43-8. doi: 10.1016/j.neuropsychologia.2010.10.026. Epub 2010 Oct 26. PubMed 21029744 ↗
  • Costa A, Bagoj E, Monaco M, Zabberoni S, De Rosa S, Papantonio AM, Mundi C, Caltagirone C, Carlesimo GA. Standardization and normative data obtained in the Italian population for a new verbal fluency instrument, the phonemic/semantic alternate fluency test. Neurol Sci. 2014 Mar;35(3):365-72. doi: 10.1007/s10072-013-1520-8. Epub 2013 Aug 21. PubMed 23963806 ↗
  • Giovagnoli AR, Del Pesce M, Mascheroni S, Simoncelli M, Laiacona M, Capitani E. Trail making test: normative values from 287 normal adult controls. Ital J Neurol Sci. 1996 Aug;17(4):305-9. doi: 10.1007/BF01997792. PubMed 8915764 ↗
  • Frasson P, Ghiretti R, Catricala E, Pomati S, Marcone A, Parisi L, Rossini PM, Cappa SF, Mariani C, Vanacore N, Clerici F. Free and Cued Selective Reminding Test: an Italian normative study. Neurol Sci. 2011 Dec;32(6):1057-62. doi: 10.1007/s10072-011-0607-3. Epub 2011 May 19. PubMed 21594655 ↗
  • Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063. PubMed 3397865 ↗
  • Royle J, Lincoln NB. The Everyday Memory Questionnaire-revised: development of a 13-item scale. Disabil Rehabil. 2008;30(2):114-21. doi: 10.1080/09638280701223876. PubMed 17852284 ↗
  • Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26. doi: 10.1111/j.1475-6773.2004.00269.x. PubMed 15230939 ↗
  • Dapor C, Devita M, Iannizzi P, Arbia E, Bruzzano A, Dessi M, Lupi D, Rolandino GM, Rossi M, Saccomano A, Siccardi E, Simonetto A, Vuerich G, Zuliani S, Priftis K. The Montreal cognitive assessment (MoCA) 8.1 version, including the memory index score (MoCA-MIS): Italian norms. Neurol Sci. 2025 Jun;46(6):2581-2589. doi: 10.1007/s10072-025-08066-1. Epub 2025 Mar 17. PubMed 40095163 ↗
  • Blasi V, Isernia S, Rossetto F, Pagliari C, Borgnis F, Pirastru A, Marzulli M, Foglia E, Garagiola E, Baglio F. Study protocol for a randomized controlled trial assessing clinical efficacy of digital cognitive rehabilitation for preclinical and mild clinical stages of alzheimer's disease continuum: the MI-RICORDO project. BMC Psychiatry. 2025 Nov 11;25(1):1075. doi: 10.1186/s12888-025-07531-7. PubMed 41219714 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Aug 2027, 22 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 22 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 14, 2025
StartActual
Oct 6, 2025
Primary completionEst.
Aug 31, 2027
CompletionEst.
Sep 30, 2027
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07064226
Lead sponsor
Fondazione Don Carlo Gnocchi ETS
Collaborators
Università Carlo Cattaneo , Castellanza, Astir s.r.l.
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Oct 6, 2025
Primary completion
Aug 31, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Feb 13, 2026

Study contacts

Valeria Blasi, MD
Contact
vblasi@dongnocchi.it
+390240308952
Chiara Pagliari, PhD
Contact
cpagliari@dongnocchi.it
+390240308952
Valeria Blasi, Medical Doctor
principal investigator · IRCCS Fondazione Don Carlo Gnocchi ONLUS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion